Your browser doesn't support javascript.
loading
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo, Imtiaz A; Klotz, Luisa; Giovannoni, Gavin; Drudge, Christopher; Haltner, Anja; Worthington, Evelyn; Zhao, Melody; Brennan, Róisín; Häring, Dieter A; Cameron, Chris; Adlard, Nicholas.
Afiliação
  • Samjoo IA; EVERSANA™, Burlington, Ontario, Canada.
  • Klotz L; Department of Neurology, University Hospital Münster, Münster, Germany.
  • Giovannoni G; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Drudge C; EVERSANA™, Burlington, Ontario, Canada.
  • Haltner A; EVERSANA™, Sydney, Nova Scotia, Canada.
  • Worthington E; EVERSANA™, Burlington, Ontario, Canada.
  • Zhao M; EVERSANA™, Burlington, Ontario, Canada.
  • Brennan R; Novartis Ireland, Dublin, Ireland.
  • Häring DA; Novartis Pharma AG, Basel 4002, Switzerland.
  • Cameron C; EVERSANA™, Sydney, Nova Scotia, Canada.
  • Adlard N; Novartis Pharma AG, Basel 4002, Switzerland. Electronic address: nicholas.adlard@novartis.com.
Mult Scler Relat Disord ; 66: 104031, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35841716
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article